Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Shanu ModiWilliam JacotToshinari YamashitaJoo Hyuk SohnMaria VidalEriko TokunagaJunji TsurutaniNaoto T UenoAleix PratYee Soo ChaeKeun Seok LeeNaoki NiikuraYeon Hee ParkBinghe XuXiaojia WangMiguel Gil-GilWei LiJean-Yves PiergaSeock-Ah ImHalle C F MooreHope S RugoRinat YerushalmiFlora ZagouriAndrea GombosSung-Bae KimQiang LiuTing LuoCristina SauraPeter SchmidTao SunDhiraj GambhireLotus YungYibin WangJasmeet SinghPatrik VitazkaGerold MeinhardtNadia HarbeckDavid A Cameronnull null

Published in: The New England journal of medicine (2022)

In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.).

Keyphrases

metastatic breast cancer
emergency department
primary care
epidermal growth factor receptor
clinical trial
study protocol
phase iii
squamous cell carcinoma
randomized controlled trial
locally advanced
phase ii
young adults
open label
tyrosine kinase